Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
3170 Porter Drive
Palo Alto, CA 94304
Phone: (650) 496 3777Website: https://www.jazzpharma.com/Careers: careers.jazzpharma.com
Latest news
- FDA Grants Accelerated Approval to Ziihera (zanidatamab-hrii) for the Treatment of HER2-Positive Biliary Tract Cancer
20 November 2024 - Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
16 September 2024 - Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer
1 June 2024 - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
29 May 2024 - Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
2 April 2024 - Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
2 June 2023 - Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
18 November 2022 - Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
12 August 2021 - FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
30 June 2021 - Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
30 March 2021
Drugs Associated with Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc manufactures, markets and/or distributes more than 8 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Defitelio
Generic name: defibrotide Drug class: miscellaneous coagulation modifiers |
||
|
Epidiolex
Generic name: cannabidiol Drug class: miscellaneous anticonvulsants |
3 reviews | 3.7 / 10 |
|
Rylaze
Generic name: asparaginase erwinia chrysanthemi Drug class: miscellaneous antineoplastics |
||
|
Vyxeos
Generic name: cytarabine liposomal/daunorubicin liposomal Drug class: antineoplastic combinations |
||
|
Xyrem
Generic name: sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
105 reviews | 7.7 / 10 |
|
Xywav
Generic name: calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
16 reviews | 8.1 / 10 |
|
Zepzelca
Generic name: lurbinectedin Drug class: alkylating agents |
||
|
Ziihera
Generic name: zanidatamab Drug class: HER2 inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
Discontinued Drugs
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
FazaClo
Generic name: clozapine Drug class: atypical antipsychotics |
||
|
Luvox CR
Generic name: fluvoxamine Drug class: selective serotonin reuptake inhibitors |
12 reviews | 7.2 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||